Atara Biotherapeutics, Inc. (ATRA) Stock Price & Analysis
Atara Biotherapeutics, Inc. (ATRA) rose 1.98% to USD 9.77 as of June 10, 2026 at 02:35 UTC, according to Nexqual real-time market data.
ATRA last closed at USD 9.58; the session ranged USD 9.42–10.15 on volume of 65,938 shares. Market capitalization is $88.03M, with a 52-week range of USD 3.92–19.15 (NMS). Source: Nexqual, June 10, 2026 at 02:35 UTC.
Key Statistics (as of June 10, 2026 at 02:35 UTC)
| Price | USD 9.77 |
|---|---|
| Change | ▲ 1.98% (up) |
| Previous Close | USD 9.58 |
| Open | USD 9.58 |
| Day Range | USD 9.42 – 10.15 |
| 52-Week Range | USD 3.92 – 19.15 |
| Volume | 65,938 shares |
| Market Cap | $88.03M |
| Exchange | NMS |
Technical Analysis (ATRA)
Nexqual's technical model rates ATRA "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.52 (neutral) |
| vs SMA50 | Above (USD 7.16) |
| MACD | 0.77 (positive) |
Analyst Ratings (ATRA)
Wall Street analysts rate ATRA "None" based on 3 analysts, with a mean price target of USD 13.67 (range USD 10–18), per Nexqual as of June 10, 2026 at 02:35 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 13.67 |
| High Target | USD 18 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (ATRA)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.35 |
| Revenue Estimate | $50,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.35 vs est -0.1 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.67 ▲ beat |
| 2025-06-30 | USD 0.19 vs est -0.32 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Financials & Fundamentals (ATRA)
| Total Revenue | $23.14M |
|---|---|
| Revenue Growth (YoY) | -99.50% |
| Gross Margin | -11.66% |
| Operating Margin | -652.91% |
| Profit Margin | -40.91% |
| Current Ratio | 2.16 |
| Total Cash | $8.36M |
| Total Debt | $9.08M |
| Free Cash Flow | $-6.39M |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Financial Health Score (ATRA)
Nexqual rates Atara Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:35 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $8M cash vs $9M debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ATRA)
| Insider Ownership | +16.66% |
|---|---|
| Institutional Ownership | +52.46% |
| Shares Outstanding | 9.01M |
| Float | 4.74M |
| Short % of Float | +7.66% |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Leadership (ATRA)
Atara Biotherapeutics, Inc. is led by Anhco Nguyen (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:35 UTC.
| President, CEO & Director | Anhco Nguyen (age 52) |
|---|---|
| Vice President of Corporate Communications & Investor Relations | Alex Chapman |
| Senior Vice President of Regulatory Affairs | Jim Sesic |
Major Backers & Investors (ATRA)
Notable institutional backers of Atara Biotherapeutics, Inc. include Adage Capital Partners GP L.L.C., Redmile Group, LLC, Mackenzie Financial Corporation, according to Nexqual as of June 10, 2026 at 02:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adage Capital Partners GP L.L.C. | 7.77% |
| Redmile Group, LLC | 4.9% |
| Mackenzie Financial Corporation | 3.48% |
| Point72 Asset Management, L.P. | 2.16% |
| Acadian Asset Management. LLC | 1.45% |
| EcoR1 Capital, LLC | 1.11% |
| Fidelity | 0.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.81% |
| BlackRock | 1% |
| Geode Capital | 0.73% |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
From Atara Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
- Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
- It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.
- The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | USD 1.82 | ▼ 3.19% |
| KYNB | Kyntra Bio, Inc. | USD 6.69 | ▼ 0.3% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:35 UTC. This page is informational and not investment advice.